Molecular Subtyping with Breast Cancer

Stefan Gluck, M.D., Ph.D., medical professor at the University of Miami, discusses a study he published in the journal Breast Cancer Research and Treatment. The study showed that women who have the common Luminal A molecular subtype of breast cancer generally receive little benefit from preoperative chemotherapy – but still have good outcomes at the five-year point. Therefore, they can safely avoid chemotherapy and its sometimes debilitating side effects. The study underlines the importance of knowing the cancer’s molecular subtype so patients can be given the most appropriate therapy. Agendia’s BluePrint is a leading genomic test for determining breast cancer molecular subtype.

• Category

  • Science & Technology

• License

  • Standard YouTube License